Jorge J Castillo1,2, Adam J Olszewski3, Zachary R Hunter1, Sandra Kanan1, Kirsten Meid1, Steven P Treon1,2. 1. Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Division of Hematology and Oncology, Memorial Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Pawtucket, Rhode Island.
Abstract
BACKGROUND: Waldenström macroglobulinemia (WM) is an indolent malignancy that predominantly affects older individuals who are at risk for secondary malignancies (SMs). The objective of this study was to characterize the incidence of SMs after a diagnosis of WM with the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: With SEER-13 data (1992-2011), standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for the rates of solid and hematologic SMs in WM patients versus the general population. The analysis was stratified by age, sex, race, year of diagnosis, and latency from the WM diagnosis. RESULTS: Among 4676 patients with WM, 681 SMs were recorded. The overall SIR was 1.49 (95% CI, 1.38-1.61), and the median time to an SM was 3.7 years. The cumulative incidence of SMs was 10% at 5 years and 16% at 10 years. The risk was significantly increased for cancers of the lungs, urinary tract, and thyroid; melanoma; aggressive lymphoma; and acute leukemia. The SIR for SMs in patients with WM was increased, regardless of age, sex, race, or year of diagnosis. CONCLUSIONS: Patients with WM had a 49% higher risk of SMs than the general population. The selectively increased risk for hematologic SMs and certain solid SMs may be associated with transformation, therapy, and immune dysregulation.
BACKGROUND: Waldenström macroglobulinemia (WM) is an indolent malignancy that predominantly affects older individuals who are at risk for secondary malignancies (SMs). The objective of this study was to characterize the incidence of SMs after a diagnosis of WM with the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: With SEER-13 data (1992-2011), standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for the rates of solid and hematologic SMs in WM patients versus the general population. The analysis was stratified by age, sex, race, year of diagnosis, and latency from the WM diagnosis. RESULTS: Among 4676 patients with WM, 681 SMs were recorded. The overall SIR was 1.49 (95% CI, 1.38-1.61), and the median time to an SM was 3.7 years. The cumulative incidence of SMs was 10% at 5 years and 16% at 10 years. The risk was significantly increased for cancers of the lungs, urinary tract, and thyroid; melanoma; aggressive lymphoma; and acute leukemia. The SIR for SMs in patients with WM was increased, regardless of age, sex, race, or year of diagnosis. CONCLUSIONS:Patients with WM had a 49% higher risk of SMs than the general population. The selectively increased risk for hematologic SMs and certain solid SMs may be associated with transformation, therapy, and immune dysregulation.
Authors: Sabrin Tahri; Tarek H Mouhieddine; Robert Redd; Luisa Lampe; Katarina I Nilsson; Habib El-Khoury; Nang Kham Su; Amin H Nassar; Elio Adib; Govind Bindra; Sarah Abou Alaiwi; Lorenzo Trippa; David P Steensma; Jorge J Castillo; Steven P Treon; Irene M Ghobrial; Adam S Sperling Journal: Blood Adv Date: 2022-04-12
Authors: C Jiménez; S Alonso-Álvarez; M Alcoceba; G R Ordóñez; M García-Álvarez; M I Prieto-Conde; M C Chillón; A Balanzategui; R Corral; L A Marín; N C Gutiérrez; N Puig; M E Sarasquete; M González; R García-Sanz Journal: Blood Cancer J Date: 2017-08-25 Impact factor: 11.037
Authors: Sarah Bertoli; Arthur Sterin; Suzanne Tavitian; Lucie Oberic; Loïc Ysebaert; Reda Bouabdallah; François Vergez; Audrey Sarry; Emilie Bérard; Françoise Huguet; Guy Laurent; Thomas Prébet; Norbert Vey; Christian Récher Journal: Oncotarget Date: 2016-12-27
Authors: Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton Journal: Br J Haematol Date: 2020-02-23 Impact factor: 8.615